The global patient-controlled analgesia pumps market accounted for USD 442.8 million in 2023 and is expected to reach at USD 838.8 million by 2034 with a CAGR of 5.98% during the forecast period 2024-2034. Increasing elderly population, a higher preference for surgical interventions, surge in technological advancements facilitating procedures in office & home care environments, rising trend of home healthcare, growing prevalence of chronic disorders such as cancer, arthritis, & pain, increasing number of individuals experiencing chronic pain, uptick in road accidents, and surge in regulatory approvals for patient-controlled analgesia pumps are some of the factors driving the market growth.
Surge in regulatory approvals for patient-controlled analgesia pumps is predicted to boost the market growth during the forecast period. Patient-controlled analgesia pumps are medical devices designed to administer medications, including pain relievers, into a patient's body at precise intervals and dosages. These devices play a crucial role in therapeutic treatments and are commonly utilized across various healthcare environments, including hospitals, outpatient clinics, private practices, and home settings. For instance, in July 2023, BD (Becton, Dickinson and Company) has disclosed that the revised BD Alaris Infusion System has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance allows for both remediation and a resumption of complete commercial activities for the most extensive infusion system accessible in the United States.
By type, electronic was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the increasing efficacy & safety of Patient-controlled Epidural Analgesia (PCEA) for childbirth & postoperative pain management, and surge in approval of novel devices by regulatory agencies. For instance, in August 2022, The FDA has cleared Baxter International Inc.'s Novum IQ infusion pump via the 510(k) regulatory procedure. The Novum IQ infusion pump is outfitted with Dose IQ safety software and the IQ Enterprise networking suite. Additionally, mechanical is predicted to grow at the fastest CAGR during the forecast period owing to its compact size, portability, affordability, absence of programming errors, & high patient satisfaction and growing preference among both healthcare professionals & patients.
By application, oncology was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the increase in the incidence of cancer cases, rise in the utilization of PCA pumps for cancer treatment in home care settings, and growing number of hospitals, ambulatory surgical centers, & specialized facilities offering pain management solutions for cancer patients. Additionally, diabetes is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of diabetes, the expanding network of partnerships & collaborations among industry participants. Patient-controlled analgesic pumps are increasingly favored for pain management in individuals with type-1 diabetes. For instance, in June 2022, BD (Becton, Dickinson and Company), a prominent global medical technology firm, and Frazier Healthcare Partners, a top private equity firm specializing solely in the healthcare sector, have entered into a definitive agreement. Under this agreement, BD will acquire Parata Systems, an inventive provider of pharmacy automation solutions, for $1.525 billion.
By end-user, hospitals was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the most smart & advanced patient-controlled analgesic pumps are readily accessible in hospitals, rising demand for advanced PCA pumps in newly established healthcare facilities, and increase in merger and acquisition activities among industry participants. For instance, in January 2022, ICU Medical Inc. has finalized the acquisition of Smith Medical from Smiths Group plc, encompassing syringe and ambulatory infusion devices. This acquisition is anticipated to offer a competitive edge to ICU Medical Inc. Additionally, home care settings is anticipated to grow at the fastest CAGR during the forecast period. Patients are increasingly favoring home care settings for cost-effective pain management. Those in hospice care or experiencing moderate to severe pain due to cancer can utilize PCA pumps in their homes.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in accidental injuries, cancer, diabetes, & other conditions requiring pain management, growing elderly population, and increase in the introduction of patient-controlled analgesic pumps. For instance, in June 2023, DoseTrac Enterprise Infusion Management Software is the most recent version of infusion management software offered by B. Braun Medical Inc. With the help of this cutting-edge platform, businesses may better understand their infusion pump fleet and related data by using tools for retrospective reporting and real-time monitoring. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the uptick in chronic disease prevalence, heightened awareness of emerging technologies, increasing recognition of pain management, surge in enhancing healthcare facilities & infrastructure, and growing regulatory approvals. For instance, in March 2022, The National Medical Products Administration (NMPA) of China has given Shanghai MicroPort Lifesciences Co., Ltd. permission to sell its AutoEx chemotherapy infusion pump. It is believed that this gadget would improve patient comfort and provide precise control over medication distribution.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in regulatory approvals for patient-controlled analgesia pumps is predicted to boost the market growth during the forecast period. Patient-controlled analgesia pumps are medical devices designed to administer medications, including pain relievers, into a patient's body at precise intervals and dosages. These devices play a crucial role in therapeutic treatments and are commonly utilized across various healthcare environments, including hospitals, outpatient clinics, private practices, and home settings. For instance, in July 2023, BD (Becton, Dickinson and Company) has disclosed that the revised BD Alaris Infusion System has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance allows for both remediation and a resumption of complete commercial activities for the most extensive infusion system accessible in the United States.
By type, electronic was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the increasing efficacy & safety of Patient-controlled Epidural Analgesia (PCEA) for childbirth & postoperative pain management, and surge in approval of novel devices by regulatory agencies. For instance, in August 2022, The FDA has cleared Baxter International Inc.'s Novum IQ infusion pump via the 510(k) regulatory procedure. The Novum IQ infusion pump is outfitted with Dose IQ safety software and the IQ Enterprise networking suite. Additionally, mechanical is predicted to grow at the fastest CAGR during the forecast period owing to its compact size, portability, affordability, absence of programming errors, & high patient satisfaction and growing preference among both healthcare professionals & patients.
By application, oncology was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the increase in the incidence of cancer cases, rise in the utilization of PCA pumps for cancer treatment in home care settings, and growing number of hospitals, ambulatory surgical centers, & specialized facilities offering pain management solutions for cancer patients. Additionally, diabetes is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of diabetes, the expanding network of partnerships & collaborations among industry participants. Patient-controlled analgesic pumps are increasingly favored for pain management in individuals with type-1 diabetes. For instance, in June 2022, BD (Becton, Dickinson and Company), a prominent global medical technology firm, and Frazier Healthcare Partners, a top private equity firm specializing solely in the healthcare sector, have entered into a definitive agreement. Under this agreement, BD will acquire Parata Systems, an inventive provider of pharmacy automation solutions, for $1.525 billion.
By end-user, hospitals was the highest revenue-grossing segment in the global patient-controlled analgesia pumps market in 2023 owing to the most smart & advanced patient-controlled analgesic pumps are readily accessible in hospitals, rising demand for advanced PCA pumps in newly established healthcare facilities, and increase in merger and acquisition activities among industry participants. For instance, in January 2022, ICU Medical Inc. has finalized the acquisition of Smith Medical from Smiths Group plc, encompassing syringe and ambulatory infusion devices. This acquisition is anticipated to offer a competitive edge to ICU Medical Inc. Additionally, home care settings is anticipated to grow at the fastest CAGR during the forecast period. Patients are increasingly favoring home care settings for cost-effective pain management. Those in hospice care or experiencing moderate to severe pain due to cancer can utilize PCA pumps in their homes.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in accidental injuries, cancer, diabetes, & other conditions requiring pain management, growing elderly population, and increase in the introduction of patient-controlled analgesic pumps. For instance, in June 2023, DoseTrac Enterprise Infusion Management Software is the most recent version of infusion management software offered by B. Braun Medical Inc. With the help of this cutting-edge platform, businesses may better understand their infusion pump fleet and related data by using tools for retrospective reporting and real-time monitoring. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the uptick in chronic disease prevalence, heightened awareness of emerging technologies, increasing recognition of pain management, surge in enhancing healthcare facilities & infrastructure, and growing regulatory approvals. For instance, in March 2022, The National Medical Products Administration (NMPA) of China has given Shanghai MicroPort Lifesciences Co., Ltd. permission to sell its AutoEx chemotherapy infusion pump. It is believed that this gadget would improve patient comfort and provide precise control over medication distribution.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Patient-controlled Analgesia Pumps Market Report 2023 - 2034
Patient-controlled Analgesia Pumps Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Mn)
- Mechanical
- Electronic
Patient-controlled Analgesia Pumps Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Gastroenterology
- Hematology
- Oncology
- Diabetes
- Others
Patient-controlled Analgesia Pumps Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Mn)
- Ambulatory Surgical Centers
- Specialty Clinics
- Hospitals
- Home Care Settings
Patient-controlled Analgesia Pumps Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Patient-controlled Analgesia Pumps Market: Type Estimates & Trend Analysis
8. Patient-controlled Analgesia Pumps Market: Application Estimates & Trend Analysis
9. Patient-controlled Analgesia Pumps Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Patient-controlled Analgesia Pumps Market
12. Europe Global Patient-controlled Analgesia Pumps Market
13. Asia Pacific Global Patient-controlled Analgesia Pumps Market
14. Latin America Global Patient-controlled Analgesia Pumps Market
15. MEA Global Patient-controlled Analgesia Pumps Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Micrel Medical Devices
- Baxter
- Avante Health Solutions
- B. Braun SE
- Terumo Corporation
- Smiths Group plc
- Ace Medical
- Fresenius SE & Co. KGaA
- Abbott
- BD
- Pfizer Inc. (Hospira)
- ICU Medical Inc.
